08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Curbed enthusiasm

Following three years of investor exuberance manifested in gains of at least 115% in biotech indices, buysiders say a good 2016 would see biotech merely keeping pace with the broader markets. Nobody is calling an...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Volatile, not futile

Bankers and buysiders are not ready to call the end of the biotech bull on the heels of the sector's worst quarter in more than 13 years. But they do expect volatility to persist through...
07:00 , Jul 13, 2015 |  BioCentury  |  Finance

Tiers, some fears

3Q15 Financial Markets Preview With biotech more than six years into a bull run, most of the sector's bankers and buysiders remain comfortable in uncharted waters because generalists are not jumping ship en masse in...
07:00 , May 4, 2015 |  BC Week In Review  |  Financial News

Anterios amends IPO

Anterios Inc. , New York, N.Y.   Business: Dermatology   Date announced: 2015-04-27   Type: IPO   To be raised: Up to $54.6 million   Shares: 3.9 million   Price: $12-$14   Underwriters: Stifel, Nicolaus;...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Financial News

Anterios proposes IPO

Anterios Inc. , New York, N.Y.   Business: Dermatology   Date announced: 2015-03-31   Type: IPO   To be raised: Up to $57.5 million   Shares: TBD   Price: TBD   Underwriters: Stifel, Nicolaus; RBC...
07:00 , Apr 6, 2015 |  BioCentury  |  Finance

Fundamental rally

2Q15 Financial Markets Preview Following three consecutive years of spectacular returns and a solid first quarter, bankers and buysiders remain confident that large caps will continue to deliver on sales and smaller companies will continue...